Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642391 · ClinicalTrials.gov registry record
Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis
A clinical trial of Cirrhosis and Adrenal Insufficiency, sponsored by University of Virginia.
- Completed
- Registry status
- 76
- Enrollment target
- 1
- Study location
NCT04642391: Completed study of Cirrhosis and Adrenal Insufficiency, sponsored by University of Virginia.
NCT04642391 is a study of Cirrhosis and Adrenal Insufficiency that has completed, run by University of Virginia. The registered enrollment target is 76 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04642391, a study of Cirrhosis and Adrenal Insufficiency, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to define the prevalence and potential pathophysiologic mechanisms underlying relative adrenal insufficiency (RAI) in outpatients with decompensated cirrhosis. Patients will be followed prospectively for up to two years to determine incidence of RAI, whether RAI represents a permanent or dynamic physiologic state in cirrhosis, and to determine whether RAI in this setting is associated with important clinical outcomes.
Conditions Studied
Interventions
- DRUG Cosyntropin
Study Locations (1)
Virginia
- University of Virginia Health System - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2024-06-30 |
What the finished NCT04642391 record still lists
NCT04642391 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which Cosyntropin is the first listed.
NCT04642391 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04642391 about?
NCT04642391 is a clinical study titled "Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis". This study aims to define the prevalence and potential pathophysiologic mechanisms underlying relative adrenal insufficiency (RAI) in outpatients with decompensated cirrhosis. Patients will be followed prospectively for up to two years to determine incidence of RAI, whether RAI represents a permanen...
What is the current status of trial NCT04642391?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2021-08-02. Estimated completion is 2024-06-30.
What conditions does trial NCT04642391 study?
This clinical trial studies the following conditions: Cirrhosis, Adrenal Insufficiency.
What interventions are being tested in trial NCT04642391?
The interventions under investigation include: Cosyntropin (DRUG).
Who is sponsoring clinical trial NCT04642391?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04642391 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04642391's enrollment target sits among peer trials
76 21st of 53 higher than 33 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
RECRUITING
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI